Adverse drug reactions and discontinuation rate during the first year on Orkambi - the earliest results of the STORM study

Authors
Category Primary study
JournalJournal of Cystic Fibrosis
Year 2019
This article has no abstract
Epistemonikos ID: 8bf74b7e55b6f5d6e5d45801eff034791900aeab
First added on: Feb 11, 2025